Aligos therapeutics is awarded €1.8m vlaio grant to advance chronic hepatitis b research

South san francisco, calif. and leuven, belgium, nov. 12, 2020 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its belgian subsidiary aligos belgium bv has been awarded a €1.8m grant by the flemish agency for innovation and entrepreneurship (vlaio) to support a nonclinical research project related to combination therapy for hepatitis b at aligos (coheba).
ALGS Ratings Summary
ALGS Quant Ranking